A clinical trials network is an essential component of an overall program to develop and test candidate HIV vaccines, and needs the scientific leadership and practical capacity to take products expeditiously from Phase I studies through efficacy trials. This application brings together participants in the UCSF AIDS Research Institute (ARI) who are leaders n the fields of virology, immunology, epidemiology, and behavioral science to design and conduct HIV vaccine trials. )ver the last decade, we have carried out pre-clinical and efficacy trial preparedness studies, single- and multi-site Phase I - III HIV vaccine trials, and laboratory support f6r all domestic and international HIV Network for Prevention Trials HIVNET) protocols. From this group of ARI investigators, the HVTN can expect expertise and leadership in the design, implementation, and laboratory support of vaccine trials. We work closely with dedicated community members to address issues of importance in the conduct of vaccine trials, and propose in this application to link domestic with international community advisory boards. """"""""Sister"""""""" sites will jointly address scientific, operational and ethical issues to help ensure that domestic and international agendas advance cooperatively. We also bring to this application substantial capacity to enroll high risk men who have sex with men (MSM) for inclusion in Phase II, Phase IIB, and Phase III vaccine trials. Data from previous studies demonstrate our success in identifying and enrolling diverse cohorts of high risk MSM in vaccine and other prevention trials; HIV seroincidence among our participants has been consistently in excess of 2 per 100 person1years, after administration of enhanced risk reduction counseling and decreases in reported risk behavior over the course of these trials. These high seroincidence rates are likely the joint result of high HIV seroprevalence in the MSM community (estimated at 30%), and identification f participants with substantial risk behavior. We have expanded our capacity to enroll high-risk MSM by inclusion of experienced sites in other Northern California locations including Santa Clara, Sacramento, Marin, and Sonoma counties. We will work within the HVTN to refine and implement a comprehensive scientific agenda for evaluating HIV vaccines, and bring substantial expertise and capacity to carry out such trials in the San Francisco HIV Vaccine Clinical Trials Unit.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI048022-05
Application #
6747289
Study Section
Special Emphasis Panel (ZAI1-HSD-A (M1))
Program Officer
Flores, Jorge E
Project Start
2000-06-01
Project End
2006-12-31
Budget Start
2004-06-01
Budget End
2006-12-31
Support Year
5
Fiscal Year
2004
Total Cost
$1,404,774
Indirect Cost
Name
Public Health Foundation Enterprises
Department
Type
DUNS #
082199324
City
City of Industry
State
CA
Country
United States
Zip Code
91746
Latkin, Carl A; Van Tieu, Hong; Fields, Sheldon et al. (2017) Social Network Factors as Correlates and Predictors of High Depressive Symptoms Among Black Men Who Have Sex with Men in HPTN 061. AIDS Behav 21:1163-1170
Janes, Holly E; Cohen, Kristen W; Frahm, Nicole et al. (2017) Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. J Infect Dis 215:1376-1385
An, Ping; Goedert, James J; Donfield, Sharyne et al. (2014) Regulatory variation in HIV-1 dependency factor ZNRD1 associates with host resistance to HIV-1 acquisition. J Infect Dis 210:1539-48
Frey, Sharon E; Peiperl, Laurence; McElrath, M Juliana et al. (2014) Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants. Clin Vaccine Immunol 21:1589-99
de Bruyn, Guy; Hudgens, Michael G; Sullivan, Patrick S et al. (2005) Participant retention in clinical trials of candidate HIV vaccines. J Acquir Immune Defic Syndr 39:499-501
Goepfert, Paul A; Horton, Helen; McElrath, M Juliana et al. (2005) High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 192:1249-59
Lee, Deborah; Graham, Barney S; Chiu, Ya-Lin et al. (2004) Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 190:903-7
de Bruyn, Guy; Rossini, Anthony J; Chiu, Ya-Lin et al. (2004) Safety profile of recombinant canarypox HIV vaccines. Vaccine 22:704-13